Phase 2 Trial of Anti-PD1 and 8 Gy in 1 Fraction for Relapse/ Refractory Myeloma

M. K. Khan,T. Nasti,T. Kleber, J. Y. Qian,J. Switchenko,C. B. Hess,K. Jonathan,A. Nooka,S. Lonial,R. Ahmed

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览1

暂无评分

摘要

Combination therapy of single-fraction, low-dose radiation therapy with pembrolizumab in patients with relapsed or refractory multiple myeloma is worth assessing in future trials.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要